- Home
- PHK vs XNCR Comparison
PHK vs XNCR Comparison
Compare PHK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHK | XNCR |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.7M | 937.1M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PHK | XNCR |
|---|---|---|
| Price | $4.66 | $16.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 669.5K | ★ 863.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $4.41 | $6.92 |
| 52 Week High | $5.04 | $18.69 |
Technical Indicators
Market Signals| Indicator | PHK | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 80.87 |
| Support Level | $4.48 | $15.69 |
| Resistance Level | $4.74 | $18.69 |
| Average True Range (ATR) | 0.05 | 0.82 |
| MACD | 0.02 | 0.40 |
| Stochastic Oscillator | 95.12 | 90.85 |
Price Performance
Historical ComparisonAbout PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. The secondary objective of the company is to seek capital appreciation.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.